Feasibility of Transdermal Delivery of Prochlorperazine
-
- Obata Yasuko
- Department of Pharmaceutics, Hoshi University
-
- Otake Yuki
- Department of Pharmaceutics, Hoshi University
-
- Takayama Kozo
- Department of Pharmaceutics, Hoshi University
この論文をさがす
抄録
Prochlorperazine (PCPZ) is used as a drug of first choice to treat opioid-induced nausea and vomiting. To examine the feasibility of the development of a transdermal drug delivery system for PCPZ, we performed an in vitro skin permeation study with hairless mouse skin. When the concentration of L-menthol in the hydrogel was 0—0.5%, the PCPZ flux was small; on the other hand, the flux was increased remarkably when the L-menthol concentration was higher than 1%. The optimal formulation of hydrogel would be contained 20% isopropanol (IPA), 10% N-methyl-2-pyrrolidone (NMP), 2% L-menthol and 1% PCPZ. The strong inhibitory effects to stereotyped behavior were observed at 4 h after administration of PCPZ hydrogel, and the efficacy was sustained for at least 8 h after the administration in mice in vivo. Thus, it was considered that PCPZ was delivered to brain via systemic circulation by the administration of PCPZ hydrogel.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 33 (8), 1454-1457, 2010
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204626655616
-
- NII論文ID
- 130000300377
-
- NII書誌ID
- AA10885497
-
- COI
- 1:STN:280:DC%2BC3cjis1Khsw%3D%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 10764782
-
- PubMed
- 20686248
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可